The Zhitong Finance App learned that on August 12, the first three companies announced that the major ADC drug “detrustuzumab” developed in collaboration with AstraZeneca has been approved for marketing. The indication is that pertuzumab is used in combination with pertuzumab for first-line treatment of adult breast cancer patients with unresectable or metastatic HER2 positive breast cancer.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.